Cantargia to run Phase 1b/2a trial of nadunolimab plus a RAS inhibitor in pancreatic cancer

Cantargia said it has preclinical data, presented at AACR Conference on Pancreatic Cancer, supporting nadunolimab with RAS inhibition in pancreatic ductal adenocarcinoma and plans a Phase 1b/2a trial.